Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
These and other observations presented in the elegant
2022-04-08

These and other observations presented in the elegant, rigorous study by Thomas et al. (2018) clarify a puzzling enigma regarding the Rab specificities of yeast TRAPP complexes and further highlight an important though under-appreciated role for the C-terminal HVD of Rabs in GEF substrate selection.
-
Continuing studies of endocannabinoid ligands at GPR reveal
2022-04-08

Continuing studies of endocannabinoid ligands at GPR55 reveal that virodhamine (O-arachidonylethanolamine) and AEA can act as a partial agonists at GPR55; at high micromolar concentrations can inhibit β-arrestin recruitment (Sharir et al., 2012). It is likely that there are allosteric as well as ort
-
br Materials and methods br Results
2022-04-08

Materials and methods Results Discussion and conclusions Our data demonstrate that native and 2-OMe-LPC analogues are GPR119 ligands and activate insulin secretion from βTC-3 pancreatic cells. LPC 18:1 was the first proposed endogenous ligand for GPR119 [1], however natural LPC has limited
-
With an ever increasing incidence rate
2022-04-08

With an ever-increasing incidence rate of type 2 diabetes and obesity, it is imperative to develop new therapeutic regimes that may provide a benefit both in terms of efficacy and tolerability. The existing portfolio of drugs for the treatment of metabolic disorders, primarily type 2 diabetes and ob
-
br FXR Agonists Azepinol b indole hEC nM
2022-04-08

FXR Agonists Azepinol[4,5-b]indole 1 (hEC50=600nM, efficacy (eff)=100%) was identified as a FXR agonist lead from a high-throughput screening effort. Structure–activity relationship (SAR) studies around the azepine ring demonstrated that dialkyl substitution at C-1 led to a 30-fold improvement in
-
Overall ABC transporters are hypothesised to prevent the pen
2022-04-08

Overall, ABC transporters are hypothesised to prevent the penetration of AEDs and other pharmacological compounds into the brain, being a hurdle for therapeutic delivery in neurological diseases. DRE is thought to be in part related to an increased expression of efflux transporters in the BBB, altho
-
br Methods and materials br Results Overall free glutamate i
2022-04-08

Methods and materials Results Overall, free glutamate intakes in US children and adults are shown in Table 1. The sample-weighted mean intake of crude free glutamate was 258 mg/d for children and 322 mg/d for adults. Furthermore, the corresponding energy-adjusted value was 136 mg/1000 kcal and
-
In the present study we set out to discover
2022-04-08

In the present study we set out to discover new non-steroidal SEGRA and to analyse their mechanism of function. Towards this goal we initiated a virtual screening (VS) approach, utilizing structure-based pharmacophore modeling, in silico docking and molecular dynamics (MD) simulations. Our pharmacop
-
Boc-D-Asp(OtBu)-OH.DCHA br Phylogenetic analysis of vertebra
2022-04-08

Phylogenetic analysis of vertebrate receptors for peptides similar to glucagon Genes for receptors for peptides similar to glucagon and other secretin-like hormones have been identified in a number of vertebrate species (Sivarajah et al., 2001, Chow et al., 2004, Irwin and Wong, 2005, Cardoso et
-
br The actions of GLP on the
2022-04-08

The actions of GLP-1 (9–36) on the vasculature/endothelium The previous sections have ascribed the vascular and/or endothelial actions of GLP-1/GLP-1R agonists to potential direct actions through a canonical GLP-1R, but as mentioned previously, whether VSMCs and ECs express a full-length GLP-1R r
-
br In vivo actions of GLP GLP R agonists on
2022-04-08

In vivo actions of GLP-1/GLP-1R agonists on the vascular endothelium Using contrast-enhanced ultrasound, male Sprague Dawley rats receiving an intravenous infusion of native GLP-1 (30 pmol/kg/min) for 2 h demonstrated significant improvements in both microvascular blood volume and microvascular b
-
hesperetin receptor The atomic model of Ce INX provides an a
2022-04-07

The atomic model of Ce-INX6 provides an additional interpretation to the Ce-INX6ΔN mutant structure at low-resolution [41]. Given that the N-terminal residues from 2 to 19 are deleted in the Ce-INX6ΔN mutant, the N-terminal funnel found in the pore of the wild-type Ce-INX6 should be lost in the Ce-I
-
Inhibitors against the proteasome a
2022-04-07

Inhibitors against the proteasome, a component of the ubiquitin-proteasome pathway that degrades cellular proteins, provide a new strategy for targeting the 26S proteasome [25]. Proteasome inhibitors can exhibit potent anti-cancer effects against different tumor Caspase Inhibitor Set I and were sho
-
br Conclusions br Acknowledgments This study was supported b
2022-04-07

Conclusions Acknowledgments This study was supported by funds from the National Natural Science Foundation of China (NSFC 31360245, 31460258) and the Applied Basic Research Foundation of Yunnan Province of China (2011FZ111). Introduction Acute myocardial infarction is the undoubted cause o
-
In early a collaborative effort
2022-04-07

In early 2017, a collaborative effort between the group that pioneered the above described evidence of platinum-induced PUFA chemotherapy resistance and a group that has contributed to much of the known molecular pharmacology of FFA4, revealed that the molecular target of 16:4(n-3), which affords ch
14646 records 453/977 page Previous Next First page 上5页 451452453454455 下5页 Last page